If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,979.50    -23.50 (-1.17%)
Bid:
1,968.50
Ask:
1,969.50
Spread: 1.00 (0.051%)
Market Cap: £79.29b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

13 Oct 2023 15:30

RNS Number : 1176Q
GSK PLC
13 October 2023
 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Emma Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on shares held through the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2080

22

d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2023-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Diana Conrad

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on shares held through the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2080

4

d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2023-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on shares held through the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2080

6

d)

Aggregated information

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2023-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on shares held through the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2080

52

d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2023-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Luke Miels

b)

Position/status

Chief Commercial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on shares held through the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2080

2

d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2023-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on shares held through the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2080

62

d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2023-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on shares held through the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2080

22

d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2023-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Phil Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on shares held through the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2080

39

d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2023-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on shares held through the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2080

51

d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2023-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Victoria Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on shares held through the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2080

48

d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2023-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Victoria Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2473

1

d)

Aggregated information

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2023-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Iain Whyte

b)

Position/status

PCA of Victoria Whyte (Company Secretary)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2473

923

d)

Aggregated information

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2023-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFFEFDDEDSESS
Date   Source Headline
13th Oct 20253:30 pmRNSDirector/PDMR Shareholding
13th Oct 20257:00 amRNSTransaction in Own Shares
10th Oct 20253:30 pmRNSDirector/PDMR Shareholding
10th Oct 20257:00 amRNSTransaction in Own Shares
9th Oct 20257:00 amRNSTransaction in Own Shares
8th Oct 20257:00 amRNSTransaction in Own Shares
7th Oct 20257:00 amRNSTransaction in Own Shares
6th Oct 20257:00 amRNSTransaction in Own Shares
3rd Oct 20257:00 amRNSTransaction in Own Shares
2nd Oct 20257:00 amRNSTransaction in Own Shares
1st Oct 20253:00 pmRNSTotal Voting Rights
1st Oct 20257:00 amRNSTransaction in Own Shares
30th Sep 20257:00 amRNSGSK - third tranche of share buyback programme
29th Sep 20257:00 amRNSGSK appoints CEO designate
22nd Sep 20253:30 pmRNSDirector/PDMR Shareholding
19th Sep 20257:00 amRNSTransaction in Own Shares
18th Sep 20257:00 amRNSTransaction in Own Shares
17th Sep 20257:00 amRNSGSK US Investment Announcement
17th Sep 20257:00 amRNSTransaction in Own Shares
16th Sep 20257:00 amRNSTransaction in Own Shares
15th Sep 20257:00 amRNSTransaction in Own Shares
12th Sep 20257:00 amRNSTransaction in Own Shares
11th Sep 20257:00 amRNSTransaction in Own Shares
10th Sep 20253:30 pmRNSDirector/PDMR Shareholding
10th Sep 20257:00 amRNSTransaction in Own Shares
9th Sep 20257:00 amRNSTransaction in Own Shares
8th Sep 20257:00 amRNSTransaction in Own Shares
5th Sep 20257:00 amRNSTransaction in Own Shares
4th Sep 20253:30 pmRNSDirector/PDMR Shareholding
4th Sep 20257:00 amRNSTransaction in Own Shares
3rd Sep 20257:00 amRNSTransaction in Own Shares
2nd Sep 20257:00 amRNSTransaction in Own Shares
1st Sep 20253:00 pmRNSTotal Voting Rights
1st Sep 20257:00 amRNSTransaction in Own Shares
29th Aug 20257:00 amRNSTransaction in Own Shares
28th Aug 20257:00 amRNSTransaction in Own Shares
27th Aug 20257:00 amRNSTransaction in Own Shares
26th Aug 20257:00 amRNSTransaction in Own Shares
22nd Aug 20257:00 amRNSTransaction in Own Shares
21st Aug 20253:30 pmRNSDirector/PDMR Shareholding
21st Aug 20257:00 amRNSTransaction in Own Shares
20th Aug 20257:00 amRNSTransaction in Own Shares
19th Aug 20253:30 pmRNSDirector/PDMR Shareholding
19th Aug 20257:00 amRNSTransaction in Own Shares
18th Aug 20257:00 amRNSTransaction in Own Shares
15th Aug 20257:00 amRNSTransaction in Own Shares
14th Aug 20257:00 amRNSTransaction in Own Shares
13th Aug 20257:00 amRNSTransaction in Own Shares
12th Aug 20253:30 pmRNSDirector/PDMR Shareholding
12th Aug 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.